Understanding Nonalcoholic Steatohepatitis (NASH): Symptoms, Causes, Treatment and Prevention

A progressive form of fatty liver disease, nonalcoholic steatohepatitis (NASH) occurs when excess fat accumulates in the liver and triggers ongoing inflammation that damages liver cells. Over time, this inflammatory fatty liver disease can lead to scarring, reduced liver function and, in some cases, liver failure or liver cancer. Although the condition has traditionally been known as NASH, some medical organizations now refer to it as metabolic dysfunction-associated steatohepatitis (MASH) to better reflect its close connection with metabolic health.

Unlike liver damage caused by excessive alcohol consumption, NASH liver disease develops in people who drink little or no alcohol. Instead, it is strongly associated with conditions such as obesity, type 2 diabetes, high cholesterol and metabolic dysfunction-associated steatotic liver disease (MASLD). Because these conditions are increasingly common, nonalcoholic steatohepatitis has become one of the leading causes of chronic liver disease worldwide.

Health care providers generally describe NASH based on the degree of liver inflammation and fibrosis rather than using terms such as mild, moderate or severe alone. Some people have active inflammation with little permanent damage, while others develop advanced fibrosis or cirrhosis after years of ongoing liver injury. Factors that can accelerate disease progression include continued weight gain, poorly controlled diabetes, metabolic syndrome and smoking.

As rates of obesity and metabolic disease continue to rise, NASH is becoming increasingly common, affecting approximately 5% of adults worldwide. In the United States, researchers estimate that 10 million to 15 million adults may be living with nonalcoholic steatohepatitis, although many have not yet been diagnosed because the condition often causes few symptoms until liver damage is advanced.

While NASH can affect adults of any age, it becomes more common with increasing age and is more likely to develop in those with multiple cardiometabolic risk factors.

How Is NASH Different From Fatty Liver Disease?

Although the terms are sometimes used interchangeably, fatty liver disease and nonalcoholic steatohepatitis are not the same condition. Simple fatty liver disease, now commonly called metabolic dysfunction-associated steatotic liver disease, occurs when fat accumulates within the liver but causes little or no inflammation or permanent damage. Many people with MASLD never develop serious liver disease.

Nonalcoholic steatohepatitis is a more advanced form of fatty liver disease. In addition to accumulating excess fat, the liver develops inflammation that injures its cells. If the condition is not recognized and managed, ongoing liver damage can increase the risk of fibrosis, cirrhosis and liver-related complications.

Not everyone with fatty liver disease will develop NASH, but identifying inflammation early can provide an opportunity to slow or even reverse disease progression before permanent scarring occurs.

What Are the Possible Complications of Nonalcoholic Steatohepatitis?

Although NASH begins in the liver, its effects can extend throughout the body. Also, because it is closely linked to metabolic disorders, it is associated with an increased risk of cardiovascular disease and other chronic health conditions.

Potential complications of nonalcoholic steatohepatitis include:

  • Liver fibrosis – Persistent inflammation can lead to fibrosis, in which scar tissue gradually replaces healthy liver tissue and impairs the liver’s ability to perform its essential functions.
  • Cirrhosis – Extensive scarring can permanently alter the structure of the liver and significantly increase the risk of liver failure.
  • Portal hypertension – Advanced cirrhosis can increase pressure within the portal vein, potentially leading to complications such as fluid accumulation in the abdomen, enlargement of the spleen and enlargement of veins in the esophagus.
  • Liver failure – Progressive liver damage may eventually prevent the liver from filtering toxins, producing clotting factors and regulating metabolism.
  • Hepatocellular carcinoma – NASH increases the risk of primary liver cancer, particularly in people with cirrhosis.
  • Cardiovascular disease – Heart attack and stroke remain leading causes of illness among people with NASH, mainly because many also have diabetes, high blood pressure or abnormal cholesterol.
  • Chronic kidney disease – Metabolic disorders associated with NASH may increase the likelihood of declining kidney function over time.

Can NASH Be Reversed?

In many cases, yes, particularly when the condition is diagnosed before advanced fibrosis or cirrhosis develops. The likelihood of reversing nonalcoholic steatohepatitis can vary depending on factors such as the degree of liver damage and the patient’s overall metabolic health and ability to achieve and maintain positive lifestyle changes.

Reducing liver fat and inflammation through weight loss, treatment of metabolic disorders and appropriate medical therapy may allow the liver to heal. Early fibrosis may also improve if the underlying cause of the inflammation is addressed. However, advanced cirrhosis is generally considered permanent, making early diagnosis especially important.

Can NASH Lead to Cirrhosis?

Yes. Persistent inflammation caused by nonalcoholic steatohepatitis can lead to the gradual replacement of healthy liver tissue with scar tissue. As the fibrosis becomes more extensive, the liver may lose its normal structure and eventually develop cirrhosis.

Not everyone with NASH progresses to cirrhosis, and the rate of progression varies considerably from person to person. Because cirrhosis often develops gradually over many years, regular medical monitoring can help identify worsening fibrosis before serious complications occur.

How Does NASH Cause Liver Damage? 

The liver normally stores only a small amount of fat. NASH causes excessive fat to accumulate inside liver cells, making the cells more vulnerable to inflammation and injury.

Over time, the damaged liver cells may release signals that activate the body’s healing response. Instead of restoring healthy tissue, repeated cycles of injury and repair can gradually produce scar tissue. As fibrosis progresses, healthy liver cells may become less able to:

  • Process nutrients and medications
  • Produce proteins that help blood clot
  • Filter toxins from the bloodstream
  • Store vitamins and minerals
  • Produce bile needed for digestion

Because the liver has a remarkable reserve capacity, these changes often occur silently for many years before symptoms become apparent.

What Is the Progression From NASH to Liver Failure?

Nonalcoholic steatohepatitis typically progresses slowly over many years. The condition often follows a continuum that begins with excess fat accumulation in the liver followed by inflammation, fibrosis and, in some cases, cirrhosis.

If cirrhosis becomes advanced, the liver may no longer function adequately, resulting in decompensated liver disease. At this stage, complications such as jaundice, fluid accumulation in the abdomen, internal bleeding, mental confusion and liver failure may develop. Some patients with advanced disease ultimately require liver transplantation.

Not everyone with NASH follows this progression. An early diagnosis and appropriate treatment can significantly reduce the likelihood of developing end-stage liver disease.

What Are the Symptoms of Nonalcoholic Steatohepatitis?

Early-stage NASH often produces few or no symptoms. In many cases, the condition is discovered only after routine blood work shows elevated liver enzymes or unrelated imaging studies reveal fatty liver changes. As inflammation and fibrosis progress, symptoms may gradually become noticeable. Recognizing potential warning signs of NASH and seeking a prompt medical evaluation can help identify liver disease before irreversible damage occurs.

Common Symptoms of Nonalcoholic Steatohepatitis

The signs of NASH can vary depending on the extent of liver inflammation and scarring. Some people may notice:

  • Fatigue – Persistent tiredness is one of the most frequently reported symptoms of nonalcoholic steatohepatitis and may interfere with work, exercise and daily activities.
  • General weakness – Ongoing liver inflammation may contribute to reduced stamina, decreased exercise tolerance and lower physical endurance.
  • Abdominal discomfort – Some people may experience a dull ache or sensation of fullness in the upper right portion of the abdomen, where the liver is located.
  • Difficulty concentrating – Some patients report problems with focus or mental clarity, particularly as liver disease progresses.
  • Unexplained weight changes – Weight fluctuations may occur, although many people with NASH are overweight or obese at the time of diagnosis.

As liver damage advances, symptoms may become more pronounced, such as jaundice, swelling of the abdomen or legs, easy bruising and physical limitations related to reduced liver function.

An immediate medical evaluation is recommended for severe abdominal swelling, mental confusion, vomiting blood, black stools, worsening jaundice or sudden changes in mental status, as these symptoms may indicate advanced liver disease or liver failure.

Uncommon Symptoms of Nonalcoholic Steatohepatitis

NASH can sometimes produce symptoms that are not immediately recognized as liver-related, such as:

  • Persistent itching
  • Loss of muscle mass
  • Sleep disturbances
  • Decreased appetite
  • Small, visible blood vessels on the skin (spider angiomas)
  • Redness of the palms
  • Hormonal changes associated with advanced cirrhosis

Many of these symptoms overlap with those of other chronic liver diseases, endocrine disorders and metabolic conditions, making a professional medical evaluation important to ensure an accurate diagnosis.

What Are the Causes and Risk Factors for Nonalcoholic Steatohepatitis?

NASH develops through a complex interaction of metabolic, genetic and environmental factors. Unlike viral hepatitis, nonalcoholic steatohepatitis is not contagious and cannot be spread from person to person. Instead, it occurs when excess fat stored in the liver triggers inflammation that damages liver cells.

Researchers continue to study the precise causes of NASH, which is widely believed to be closely linked to metabolic health. Conditions such as obesity, insulin resistance and type 2 diabetes can increase the likelihood that fatty liver disease will progress to inflammatory fatty liver disease.

Causes of Nonalcoholic Steatohepatitis

Although no single factor is known to cause NASH, several biological processes may contribute to its development. These include:

  • Excess fat accumulation in the liver – When the liver stores more fat than it can safely process, liver cells may become more susceptible to inflammation and damage.
  • Insulin resistance – One of the primary drivers of NASH, insulin resistance alters the body’s ability to regulate blood sugar and fat metabolism, increasing fat deposition in the liver.
  • Metabolic dysfunction – Obesity, abnormal cholesterol levels and high triglycerides can contribute to chronic inflammation that may accelerate liver damage.
  • Genetic predisposition – Certain inherited genetic variants, including changes in the PNPLA3 and TM6SF2 genes, appear to increase the risk of developing NASH and advanced fibrosis.
  • Oxidative stress – Excess fat within liver cells can generate harmful molecules that damage tissues and promote inflammation.
  • Changes in the gut microbiome – Emerging research suggests that alterations in intestinal bacteria may influence inflammation and liver metabolism in some people.
  • Hormonal and metabolic changes – Conditions that affect hormone regulation, including insulin resistance and polycystic ovary syndrome (PCOS), may contribute to NASH development.

Risk Factors for Nonalcoholic Steatohepatitis

Several medical conditions and lifestyle factors are believed to increase the likelihood of developing NASH liver disease. Many are components of metabolic syndrome, a group of disorders that affect how the body processes and stores energy. Risk factors for nonalcoholic steatohepatitis include:

  • Obesity – Excess body weight, particularly “belly fat,” is one of the strongest risk factors for NASH.
  • Type 2 diabetes – Poorly controlled blood sugar can significantly increase the likelihood of liver inflammation and fibrosis.
  • Metabolic syndrome – A combination of abdominal obesity, elevated blood sugar, high blood pressure and abnormal cholesterol can greatly increase the risk of progressive fatty liver disease.
  • Insulin resistance or prediabetes – Even before diabetes develops, insulin resistance can contribute to fat accumulation in the liver.
  • High cholesterol or elevated triglycerides – Abnormal blood lipid levels are frequently associated with nonalcoholic steatohepatitis.
  • High blood pressure – Hypertension commonly occurs alongside other metabolic risk factors for NASH.
  • Polycystic ovary syndrome – Women with PCOS have higher rates of insulin resistance and fatty liver disease.
  • Sleep apnea – Repeated reductions in oxygen levels during sleep may contribute to liver inflammation.
  • Family history – Although NASH is not inherited directly, a family history of fatty liver disease, type 2 diabetes or obesity may increase susceptibility.
  • Sedentary lifestyle – Limited physical activity can contribute to obesity, insulin resistance and metabolic dysfunction.
  • Tobacco use – Smoking does not cause NASH, but it may worsen inflammation and increase the risk of cardiovascular disease.
  • Poor nutrition – A diet high in added sugars, refined carbohydrates and saturated fats may promote fat accumulation within the liver.

It is important to note that some people develop NASH despite maintaining a body weight within the recommended range. This is sometimes called “lean NASH” and may be related to genetic factors, body fat distribution or underlying metabolic abnormalities.

Risk Factors for Progressive Liver Disease

Not everyone with NASH experiences the same rate of disease progression. While some people remain stable for many years, others develop advanced fibrosis, cirrhosis or liver failure. Factors associated with more rapid NASH progression include:

  • Advanced liver fibrosis at the time of diagnosis
  • Poorly controlled type 2 diabetes
  • Persistent obesity or continued weight gain
  • Metabolic syndrome affecting multiple organ systems
  • Older age
  • Ongoing smoking
  • Coexisting chronic liver diseases
  • Cardiovascular disease or chronic kidney disease
  • Limited physical activity and poor long-term metabolic control

Through regular follow-up, the health care team may identify changes in liver health early and adjust the treatment strategy before irreversible complications develop.

How Is Nonalcoholic Steatohepatitis Diagnosed?

Diagnosing NASH involves more than identifying fat in the liver. The physician must determine whether inflammation and fibrosis are also present while excluding other possible causes of liver disease. Because many people have few or no symptoms, nonalcoholic steatohepatitis is often discovered through routine blood work or imaging performed for another reason. Modern NASH diagnosis increasingly relies on noninvasive testing to estimate liver fibrosis, although a liver biopsy may still be recommended in select situations.

Clinical Assessment for Nonalcoholic Steatohepatitis

Typically, the physician will begin with a detailed health history and physical examination. A broad understanding of the patient’s overall health and metabolic risk factors can provide the physician with important insights about the likelihood of NASH and guide decisions about additional testing. During the initial evaluation, the physician may ask about:

  • Body weight history and recent changes
  • Diet and physical activity
  • Type 2 diabetes, prediabetes or insulin resistance
  • Blood pressure 
  • Cholesterol
  • Current medications and dietary supplements
  • Alcohol consumption
  • Personal or family history of liver disease
  • Symptoms such as fatigue, abdominal discomfort and swelling

The physical examination may reveal signs associated with metabolic disease, including central obesity, elevated blood pressure or skin changes related to insulin resistance. The physician may also check for jaundice, abdominal fluid accumulation, muscle wasting, spleen enlargement or swelling in the legs, which could indicate advanced liver disease.

Diagnostic Tests and Procedures for Nonalcoholic Steatohepatitis

Several tests may be used together to evaluate liver inflammation, estimate fibrosis and confirm a diagnosis of NASH. Common diagnostic studies include:

  • Liver function tests – Blood work that measures ALT, AST, alkaline phosphatase, bilirubin, albumin and clotting function can help the physician assess liver injury and function.
  • Complete blood count (CBC) and metabolic panel – These tests provide important information about platelet counts, kidney function, blood sugar and other indicators of overall health.
  • Fibrosis risk scores – Calculations such as the FIB-4 Index and NAFLD Fibrosis Score use laboratory values and clinical information to estimate the likelihood of advanced fibrosis.
  • FibroScan® (transient elastography) – This specialized ultrasound-based test can measure liver stiffness and help the physician estimate the degree of fibrosis without surgery.
  • Abdominal ultrasound – This test is often the first imaging study used to detect excess fat in the liver.
  • Magnetic resonance imaging (MRI)-based tests – MRI proton density fat fraction (MRI-PDFF) and MR elastography may provide a more detailed assessment of liver fat and fibrosis in select patients.
  • Liver biopsy – Considered the gold standard for confirming NASH, a biopsy can identify fat accumulation, inflammation and liver cell damage while determining the stage of fibrosis. However, it is generally reserved for cases in which the diagnosis remains uncertain or when the results are expected to influence treatment decisions.
  • Upper endoscopy – Patients with advanced cirrhosis may undergo endoscopy to check for esophageal or gastric varices caused by portal hypertension.

Other Conditions That May Resemble NASH

Several liver disorders can resemble nonalcoholic steatohepatitis and produce similar clinical and laboratory findings. A careful evaluation can help determine the underlying cause and ensure appropriate treatment is selected. Conditions that may be considered during the diagnostic process for NASH include:

  • Metabolic dysfunction-associated steatotic liver disease – In MASLD, fat accumulates in the liver without the inflammation and liver cell injury characteristic of NASH.
  • Alcohol-associated liver disease – Excessive alcohol consumption can produce inflammation and fibrosis similar to NASH.
  • Chronic viral hepatitis – Hepatitis B and hepatitis C may cause elevated liver enzymes and progressive fibrosis.
  • Autoimmune hepatitis – An immune-mediated condition can sometimes cause chronic liver inflammation.
  • Drug-induced liver injury – Certain prescription medications, herbal products and supplements may damage the liver.
  • Hereditary liver disorders – Conditions such as hemochromatosis, Wilson’s disease and alpha-1 antitrypsin deficiency may mimic fatty liver disease.
  • Liver cancer – Hepatocellular carcinoma may arise in patients with cirrhosis from NASH or other liver diseases.

A diagnosis of nonalcoholic steatohepatitis is based on a combination of clinical findings, laboratory testing and imaging, with a liver biopsy performed when necessary to confirm inflammation and stage fibrosis. A patient with advanced fibrosis or cirrhosis may be referred for specialized liver care or liver transplant evaluation if significant liver dysfunction is present.

What Treatments Are Available for Nonalcoholic Steatohepatitis?

NASH treatment focuses on reducing liver inflammation, slowing or reversing fibrosis when possible and addressing the underlying metabolic conditions that contribute to disease progression. Unlike viral hepatitis, nonalcoholic steatohepatitis cannot be cured with a single medication. Instead, its treatment typically combines lifestyle changes, management of obesity and diabetes, medications for eligible patients and regular monitoring of liver health. The earlier NASH is diagnosed, the greater the opportunity to prevent permanent liver damage and reduce the risk of cirrhosis or liver failure.

Lifestyle Modifications for Nonalcoholic Steatohepatitis

Lifestyle changes are considered the foundation of NASH treatment. Even modest improvements in body weight and metabolic health can reduce liver fat and inflammation while slowing disease progression. Common recommendations include:

  • Achieve gradual, sustained weight loss – When necessary, losing approximately 7% of body weight can reduce liver inflammation, and greater weight loss may improve fibrosis in some patients.
  • Follow a heart-healthy eating pattern – Consuming a Mediterranean-style diet rich in vegetables, fruits, whole grains, legumes, fish and healthy fats while limiting added sugars and processed foods may help reduce liver fat.
  • Work with a registered dietitian when appropriate – Individualized nutrition counseling can support long-term success and sustainable lifestyle changes.
  • Exercise regularly – In general, most people should aim for at least 150 minutes of moderate physical activity each week, along with strength training when appropriate. Exercise can benefit the liver even when significant weight loss is not achieved.
  • Control diabetes – Careful blood sugar management can help reduce metabolic stress on the liver.
  • Manage cholesterol and blood pressure – Treating other components of metabolic syndrome, such as abnormal cholesterol and hypertension, can support both liver health and cardiovascular health.
  • Avoid tobacco use – Smoking can contribute to cardiovascular disease and may worsen long-term health outcomes.
  • Limit or avoid alcohol consumption – Although NASH is not caused by alcohol, drinking may accelerate liver damage in people who already have liver disease.

Medications for Nonalcoholic Steatohepatitis

Medication may be recommended for certain patients based on the severity of the liver disease, the stage of the fibrosis and any coexisting medical conditions. In addition to treating NASH itself, medications can improve diabetes, obesity or cardiovascular risk, playing an important role in overall disease management. Commonly prescribed medications and supplements include:

  • Resmetirom (Rezdiffra®) – Rezdiffra is the first FDA-approved medication specifically indicated for certain adults with noncirrhotic NASH and moderate to advanced liver fibrosis. It works by activating thyroid hormone receptor-beta in the liver to reduce fat accumulation and inflammation. Possible side effects include diarrhea, nausea and itching. Liver function should be monitored during treatment.
  • GLP-1 receptor agonists – Medications such as semaglutide or tirzepatide are approved for diabetes and, in some cases, obesity. Although not currently approved specifically for NASH, these drugs may promote substantial weight loss and improve metabolic health, which can benefit many patients with fatty liver disease.
  • Pioglitazone – This medication may be considered for certain patients, particularly those with type 2 diabetes, because it can improve insulin sensitivity and liver inflammation. Potential side effects include weight gain, fluid retention and an increased risk of fractures.
  • Vitamin E – In carefully selected patients without diabetes, vitamin E supplementation may improve liver inflammation. Because long-term use is not appropriate for everyone, the patient should discuss the potential risks and benefits with their health care provider.

There are currently no anti-inflammatory medications, immunosuppressive drugs or over-the-counter supplements proven to cure NASH. The patient should always consult their health care team before taking any herbal product or dietary supplement, as some can potentially worsen liver damage or interact with prescribed medications.

Monitoring Nonalcoholic Steatohepatitis and Preventing Cirrhosis

Ongoing follow-up is an important part of liver disease management for patients with NASH. Even when symptoms improve, fibrosis can continue to progress if the underlying metabolic risk factors remain uncontrolled. Continuing care may include:

  • Periodic liver function tests
  • Fibrosis assessment using FibroScan® or other noninvasive tests
  • Blood-based fibrosis scores, such as the FIB-4 Index
  • Monitoring blood sugar, cholesterol and blood pressure
  • Body weight and body composition assessments
  • Liver cancer surveillance for patients with cirrhosis

Routine monitoring can allow the health care team to detect worsening fibrosis early, evaluate the treatment response and modify the treatment plan when necessary.

Medical Procedures for Nonalcoholic Steatohepatitis

Although surgery is not performed to treat NASH itself, several medical or surgical procedures may be considered if advanced liver disease or severe obesity is present. These include:

  • Liver biopsy – A biopsy may be recommended to confirm the diagnosis, determine the fibrosis stage or evaluate an uncertain case.
  • Bariatric (metabolic) surgery – A carefully selected patient with severe obesity may benefit from weight-loss surgery, which can improve metabolic health and may reduce liver fat and inflammation over time.
  • Endoscopy – A patient with cirrhosis may undergo upper endoscopy to screen for enlarged veins in the esophagus or stomach.
  • Paracentesis – This procedure can remove excess abdominal fluid (ascites) that may occur with advanced cirrhosis.
  • Liver cancer treatment – If hepatocellular carcinoma develops, treatment options may include tumor ablation, embolization, surgery, radiation therapy or systemic therapy, depending on the extent of the cancer.

Liver Transplant Implications

Some people with NASH may eventually develop end-stage liver disease despite treatment. If cirrhosis leads to liver failure or certain cases of liver cancer, liver transplantation may be the most appropriate treatment option.

Before transplantation, the patient will undergo a comprehensive evaluation to assess their liver function, overall health, nutritional status and other medical conditions. Because obesity, diabetes and cardiovascular disease are common in people with NASH, optimizing these conditions is an essential aspect of transplant preparation.

Following transplantation, ongoing management of metabolic health remains important because fatty liver disease can recur if underlying risk factors are not addressed.

Clinical Trials for Nonalcoholic Steatohepatitis

Researchers continue to investigate new approaches to treating NASH, including medications that target liver inflammation, fibrosis, fat metabolism and insulin resistance. Several promising therapies are currently being evaluated in clinical trials, both as individual medications and in combination with lifestyle interventions.

For some patients, participation in a clinical trial may provide access to an emerging therapy as well as an opportunity to contribute to future advances in NASH treatment. Eligibility depends on factors such as the patient’s fibrosis stage, overall health and previous treatments.

What Is the Prognosis and Long-Term Outlook for Nonalcoholic Steatohepatitis?

The outlook for individuals with NASH varies considerably. Some people may experience slow disease progression with minimal long-term liver damage, while others might develop advanced fibrosis, cirrhosis or liver failure over time. An early diagnosis, sustained weight management and effective control of metabolic conditions can significantly reduce the likelihood of serious complications and improve the long-term outcome.

Living Well With Nonalcoholic Steatohepatitis

Living with NASH often requires long-term attention to liver health and metabolic wellness. Small, sustainable lifestyle changes can have a meaningful impact on disease progression. Helpful strategies include:

  • Taking medications exactly as prescribed.
  • Following the recommended liver monitoring schedule if advanced fibrosis or cirrhosis is present.
  • Staying physically active.
  • Choosing nutritious meals that support weight management.
  • Avoiding smoking and limiting or avoiding alcohol consumption.
  • Managing diabetes, cholesterol and high blood pressure.
  • Discussing new medications or supplements with a physician before starting them.
  • Seeking medical attention promptly if symptoms such as jaundice, abdominal swelling or confusion occur.

Weight Loss and Metabolic Health

Weight management remains one of the most effective treatments for NASH. Even modest, sustained weight loss can improve liver fat, reduce inflammation and slow fibrosis progression. The patient should focus on gradual lifestyle changes rather than rapid weight-loss strategies, which can be difficult to maintain. A comprehensive plan that includes nutrition, physical activity, behavioral support and treatment of obesity-related conditions often provides the greatest long-term benefit.

Monitoring Fibrosis Progression

Because fibrosis often develops silently, regular monitoring is important even when the patient feels well. Periodic blood tests, imaging studies and noninvasive fibrosis assessments can help the health care team evaluate liver health over time. A patient with advanced fibrosis or cirrhosis may also require ongoing liver cancer surveillance and additional testing to identify complications before they become severe.

Support for Those Living With Nonalcoholic Steatohepatitis

Family members and friends can play an important role in helping  the patient successfully manage NASH. Encouragement and practical support often make long-term lifestyle changes easier to maintain. Loved ones can help by:

  • Participating in healthy meal planning and physical activity.
  • Encouraging adherence to medications and follow-up appointments.
  • Learning about NASH and its connection to metabolic health.
  • Offering emotional support during periods of lifestyle adjustment.
  • Celebrating realistic, sustainable health improvements rather than focusing solely on weight.

Caregivers should also prioritize their own health by managing stress, maintaining regular medical care and seeking support when needed. 

Long-Term Outlook and Emerging Therapies for NASH

Although nonalcoholic steatohepatitis cannot always be completely reversed, it can often be successfully managed through lifestyle changes, treatment of metabolic conditions and, for appropriate patients, medication. Many people are able to slow disease progression and preserve liver function for years. The prognosis depends largely on the amount of liver fibrosis present at diagnosis and how effectively metabolic risk factors are controlled. Patients who develop cirrhosis require lifelong monitoring because they remain at increased risk for liver failure and liver cancer.

Research into NASH continues to advance rapidly. Investigators are currently evaluating the effectiveness of new medications that target fibrosis, inflammation, fat metabolism and insulin resistance, as well as combination therapies that may further improve outcomes. As the scientific understanding of NASH evolves, treatment options are expected to continue expanding, offering new opportunities to slow disease progression and improve long-term liver health.

What Are the Mental, Emotional and Social Effects of Nonalcoholic Steatohepatitis?

NASH affects more than the liver. Managing a chronic health condition that requires long-term lifestyle changes, weight management and ongoing medical follow-up can take an emotional toll. Many patients also must cope with coexisting conditions, such as obesity, type 2 diabetes or cardiovascular disease, which may further affect quality of life. Recognizing the emotional and social aspects of NASH is an important part of comprehensive care.

Potential Mental Health Effects of Nonalcoholic Steatohepatitis

Receiving a diagnosis of NASH may create uncertainty about future health, particularly if fibrosis or cirrhosis has already developed. Lifestyle changes can also feel overwhelming, especially when multiple medical conditions require attention at the same time. Potential mental health effects of NASH include:

  • Anxiety about liver disease progression or future complications
  • Depression related to managing a chronic illness
  • Frustration with long-term dietary or weight management goals
  • Stress associated with frequent medical appointments and testing
  • Feelings of guilt or self-blame related to body weight or metabolic health

It is important for the patient to keep in mind that nonalcoholic steatohepatitis is a complex medical condition influenced by genetics, metabolism and environmental factors. It is not simply the result of personal choices.

Mental health professionals, registered dietitians, diabetes educators and support groups can help the patient develop practical coping strategies while building sustainable lifestyle habits. Regular physical activity, good sleep, stress management and strong social connections may also improve emotional well-being.

Social, Family and Workplace Considerations

Most people with nonalcoholic steatohepatitis can continue working, traveling and participating in other daily activities, particularly during the early stages of the condition. However, fatigue and other symptoms may occasionally affect productivity or limit participation in physically demanding tasks.

Some people may find it challenging to maintain dietary changes at social gatherings, restaurants and workplace events where healthier options may be limited. Planning ahead, packing nutritious meals or snacks and communicating dietary goals with family and friends can help support long-term success.

Family members often play an integral role by encouraging healthy eating habits, maintaining regular physical activity and supporting medical appointments. Because positive lifestyle changes can benefit everyone in the household, many families find that making healthy choices together is easier than asking one person to make changes alone.

Can Nonalcoholic Steatohepatitis Be Prevented?

Although not every case of NASH can be prevented, many people can lower their risk by improving their metabolic health and addressing conditions that may contribute to fatty liver disease. Early recognition of metabolic risk factors can provide an opportunity to reduce liver inflammation before permanent scarring develops. Strategies for preventing NASH include include:

  • Maintaining a healthy body weight – Preventing excess weight gain is one of the most effective ways to reduce the risk of NASH.
  • Staying physically active – Regular exercise can help improve insulin sensitivity, reduce liver fat and support cardiovascular health.
  • Opting for a balanced eating pattern – Emphasizing vegetables, fruits, whole grains, lean proteins and healthy fats while limiting added sugars and highly processed foods can support liver health.
  • Managing type 2 diabetes or prediabetes – Good blood sugar control may help reduce liver inflammation and slow NASH progression.
  • Controlling cholesterol and blood pressure – Treating metabolic syndrome can help protect both the liver and the cardiovascular system.
  • Avoiding tobacco use – Smoking can contribute to chronic disease and worsen long-term health outcomes.
  • Limiting or avoiding alcohol consumption – Although alcohol does not cause NASH, it can increase liver damage in people with underlying liver disease.
  • Scheduling routine medical checkups – Regular visits can allow the health care team to identify and address metabolic risk factors and abnormal liver tests early.
  • Discussing screening if appropriate – People with obesity, type 2 diabetes or metabolic syndrome may benefit from an evaluation for fatty liver disease even if they do not have symptoms.

Because nonalcoholic steatohepatitis often develops silently, routine medical care and early intervention are essential for preventing advanced fibrosis, cirrhosis and liver failure.

The TGH Difference for Nonalcoholic Steatohepatitis

Effective management of NASH requires specialized expertise in liver disease and the metabolic conditions that may contribute to its progression. At Tampa General Hospital, patients can receive comprehensive, personalized care designed to identify liver damage early, slow disease progression and preserve long-term liver function.

The specialists within the TGH Transplant Institute work closely with experts in hepatology, endocrinology, nutrition, weight management and transplant surgery to develop individualized treatment plans for patients with nonalcoholic steatohepatitis. Advanced diagnostic tools, including noninvasive liver fibrosis assessments and comprehensive metabolic evaluations help guide treatment decisions while reducing the need for invasive testing whenever possible.

For patients with advanced fibrosis, cirrhosis or end-stage liver disease, TGH offers coordinated evaluations and treatments through one of the nation’s leading liver transplant programs. Our patients benefit from the collaboration of a multispecialty team that provides seamless care before, during and after transplantation.

Whether you were recently diagnosed with nonalcoholic steatohepatitis, are concerned about fatty liver disease or require specialized treatment for advanced liver disease, the experts at Tampa General Hospital can provide compassionate, evidence-based care to help you achieve the best possible long-term outcome.